We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Moderna (MRNA) Gains As Market Dips: What You Should Know
Read MoreHide Full Article
In the latest trading session, Moderna (MRNA - Free Report) closed at $137.74, marking a +1.38% move from the previous day. This change outpaced the S&P 500's 0.72% loss on the day. Elsewhere, the Dow lost 0.45%, while the tech-heavy Nasdaq lost 0.27%.
Coming into today, shares of the biotechnology company had lost 9.43% in the past month. In that same time, the Medical sector lost 5.59%, while the S&P 500 lost 9.06%.
Investors will be hoping for strength from Moderna as it approaches its next earnings release. The company is expected to report EPS of $5.20, down 32.47% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $4.92 billion, down 1.04% from the prior-year quarter.
MRNA's full-year Zacks Consensus Estimates are calling for earnings of $26.41 per share and revenue of $22.29 billion. These results would represent year-over-year changes of -6.65% and +20.7%, respectively.
Any recent changes to analyst estimates for Moderna should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.07% lower. Moderna is currently a Zacks Rank #3 (Hold).
Investors should also note Moderna's current valuation metrics, including its Forward P/E ratio of 5.14. This represents a discount compared to its industry's average Forward P/E of 20.38.
Also, we should mention that MRNA has a PEG ratio of 0.79. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. MRNA's industry had an average PEG ratio of 1.36 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 76, which puts it in the top 31% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow MRNA in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Moderna (MRNA) Gains As Market Dips: What You Should Know
In the latest trading session, Moderna (MRNA - Free Report) closed at $137.74, marking a +1.38% move from the previous day. This change outpaced the S&P 500's 0.72% loss on the day. Elsewhere, the Dow lost 0.45%, while the tech-heavy Nasdaq lost 0.27%.
Coming into today, shares of the biotechnology company had lost 9.43% in the past month. In that same time, the Medical sector lost 5.59%, while the S&P 500 lost 9.06%.
Investors will be hoping for strength from Moderna as it approaches its next earnings release. The company is expected to report EPS of $5.20, down 32.47% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $4.92 billion, down 1.04% from the prior-year quarter.
MRNA's full-year Zacks Consensus Estimates are calling for earnings of $26.41 per share and revenue of $22.29 billion. These results would represent year-over-year changes of -6.65% and +20.7%, respectively.
Any recent changes to analyst estimates for Moderna should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.07% lower. Moderna is currently a Zacks Rank #3 (Hold).
Investors should also note Moderna's current valuation metrics, including its Forward P/E ratio of 5.14. This represents a discount compared to its industry's average Forward P/E of 20.38.
Also, we should mention that MRNA has a PEG ratio of 0.79. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. MRNA's industry had an average PEG ratio of 1.36 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 76, which puts it in the top 31% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow MRNA in the coming trading sessions, be sure to utilize Zacks.com.